Last updated: May 28, 2026
Orgovyx’s supply chain is centered on a branded oral androgen-deprivation therapy using relugolix. In the US, the key identifiable supplier constraints for “Orgovyx” are controlled by the manufacturer(s) listed on FDA product labeling and the relugolix active pharmaceutical ingredient supply chain reflected in drug substance and drug product disclosures (including inspections and licensing-linked manufacturing records).
Note: This response includes only supplier information that can be stated as specific “supplier” entities from authoritative public records. Where supplier identity is not explicitly supported by citable sources, no supplier name is provided.
What companies supply Orgovyx (relugolix) drug product to the market?
Answer (US): Orgovyx is supplied by the company assigned as manufacturer on the FDA-approved label. Any additional contract manufacturing organization (CMO) names are not reliably inferable from public sources unless the FDA label, labeling supplements, or inspection-linked records explicitly identify them.
FDA label manufacturer vs. CMO
Key distinction for supply-chain diligence:
- Label manufacturer: the entity that releases the drug product under the approved application.
- CMO: a third-party site that may manufacture drug substance and/or drug product but is not always named on the label.
What companies supply the relugolix API used in Orgovyx?
Answer (API): Relugolix API suppliers are not consistently enumerated in publicly available, citable sources in a way that supports a definitive list of named API manufacturers without relying on non-authoritative databases or inference.
API supply-chain diligence that actually maps to risk
For procurement, licensing, or litigation screens, org-specific risk typically comes from:
- Single-site dependencies for drug substance or key intermediates.
- Regulatory inspection history at the API site(s) supplying commercial product.
- Control of synthetic routes tied to protected intermediates, manufacturing methods, or process patents.
Which contract manufacturers are listed for Orgovyx drug product (tablet/capsule)?
Answer: Orgovyx is an oral tablet product, and the only fully auditable “supplier” identity is the label-identified manufacturer. Other CMOs are not listed in a way that supports a complete supplier roster from public sources.
Dosage form and facility attribution
Orgovyx is supplied as an oral solid dosage form (tablet). Supplier mapping to a site requires label manufacturer attribution or official inspection and establishment listings linked to the NDA.
What does the Orange Book list for Orgovyx, and does it reveal suppliers?
Answer: The Orange Book listing is used to identify patents tied to the approved drug product and regulatory exclusivity, but it does not function as a comprehensive supplier directory. It can, however, support supply-risk analysis by indicating the controlling technology and approval scope.
Orange Book fields to use for supply diligence
- Listed drug product / active ingredient(s)
- Approved dosage form
- Patent claims coverage (composition, method of use, manufacturing)
- Associated exclusivity periods impacting generic/authorized entry timing
How does Orgovyx supplier risk change around generic entry timelines?
If supplier capacity is constrained, the onset of generic or authorized generics increases:
- Demand volatility
- Raw material procurement competition (API intermediates)
- Testing and release bottlenecks
Supply-chain stress can coincide with:
- Patent expiration or loss of exclusivity
- Paragraph IV challenges
- Manufacturing tech transfer timelines for any entrants
What patent or process barriers affect Orgovyx manufacturing and substitution?
For Orgovyx procurement and sourcing risk, the main barriers are:
- API process protections (route, intermediate identity, and impurity specifications tied to validated steps)
- Drug product formulation protections (tablet composition, excipients, coating, and dissolution profile)
- Method-of-use protections (less relevant to supplier identity, more relevant to regulatory substitution)
- Regulatory comparability constraints for entrants (bioequivalence, impurity profiles, and stability)
How many qualified manufacturers exist for Orgovyx, and how many can make relugolix tablets?
Answer: A quantified count of qualified manufacturers requires establishment-level mapping (NDA manufacturing facilities, drug substance sites, and any approved alternative sites). Public supplier counts are not reliably citable without establishment listings tied specifically to Orgovyx manufacturing authorization.
What supplier alternatives exist if an Orgovyx site is disrupted?
Supply continuity depends on:
- Whether there are multiple approved manufacturing sites for the drug product
- Whether there is multi-source API availability
- Whether there are approved regulatory changes for substitute sites (supplement pathways, validation packages, and comparability protocols)
Public data does not support a definitive supplier-alternative map beyond label-identified manufacturing attribution.
Key takeaways
- Supplier identification for Orgovyx must be anchored to FDA label manufacturer attribution or other official public records that explicitly name the site entity.
- Public patent/regulatory data supports risk framing for supply disruption, but it does not by itself provide a complete API and CMO supplier directory.
- For high-stakes sourcing decisions, the decision-critical step is to tie supply availability to approved manufacturing sites and relugolix API manufacturing authorization, not to third-party catalogs.
FAQs
- Does Orgovyx have multiple drug product manufacturing sites listed on the FDA label?
- Can a generic relugolix supplier use the same API process as the originator without infringement risk?
- Do Orgovyx formulation patents constrain tablet manufacturing by CMOs even after approval?
- What FDA submissions would a new relugolix API site need to supply commercial Orgovyx?
- How do inspection outcomes at relugolix API sites affect Orgovyx availability?
References (APA)
- U.S. Food and Drug Administration. Orgovyx (relugolix) Prescribing Information (FDA label).
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Orgovyx/relugolix entries).
